Equities
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)0.915
  • Today's Change0.005 / 0.55%
  • Shares traded332.29k
  • 1 Year change-93.34%
  • Beta--
Data delayed at least 15 minutes, as of Feb 03 2023.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Nordic Nanovector ASA is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.

  • Revenue in NOK (TTM)0.00
  • Net income in NOK-434.14m
  • Incorporated2009
  • Employees40.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
NANOV:OSL since
announced
Transaction
value
Apim Therapeutics AsAnnounced21 Nov 202221 Nov 2022Announced-18.30%--
Apim Therapeutics AsAnnounced09 Nov 202209 Nov 2022Announced-33.70%50.09m
Data delayed at least 15 minutes, as of Feb 03 2023.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Oncozenge AB0.00-41.87m77.81m----2.10-----3.69-3.690.003.260.00-------69.60---72.18--------------0.00--------------
Prolight Diagnostics AB (publ)0.00-7.71m85.13m----0.2845-----0.0533-0.05330.001.090.00-------4.96-5.03-5.05-5.18------------0.00-------59.41---52.37--
Dextech Medical AB0.00-4.98m86.76m1.00--2.35-----0.2966-0.29660.002.060.00-------23.11-36.80-23.29-38.28------------0.00------13.26---18.38--
PCI Biotech Holding ASA4.75m-73.45m86.78m17.00--1.37--18.26-1.97-1.970.12731.700.0416--0.5862279,529.40-64.25-33.17-72.79-36.55-----1,545.58-762.80----0.0221---14.86-9.75-22.36------
ISR Immune System Rgultn Hldg AB (publ)0.00-249.37m93.69m-----------3.65-3.650.00-2.390.00-------1,169.75-111.37---155.17-----------128,581.00---------152.98------
Lidds AB4.24m-35.55m101.33m3.00--2.23--23.92-0.9805-0.98050.11660.67330.0874--8.89---73.34-18.73-88.78-19.85-----839.40-878.39---18,330.500.00--930.15---15.27---29.79--
Lipum AB (publ)0.00-52.60m103.91m----23.78-----11.98-11.980.000.58860.00-------144.61---166.87--------------0.3449---100.00---147.69------
Nordic Nanovector ASA0.00-434.14m106.17m40.00--0.5816-----4.20-4.200.001.570.00----0.00-107.68-69.82-153.00-88.28-------636,940.80----0.00-------5.81---29.60--
Bioextrax AB publ529.36k-15.30m106.52m----4.44--201.22-1.01-1.010.03470.9710.0332--3.26---95.97---123.03---86.52---2,890.40-----22,539.960.00--1,166.12---89.02------
Scandion Oncology A/S-96.97bn-96.97bn113.95m----0.8982----------3.21----------------------------0.0072-------217.81------
Isofol Medical AB (publ)15.17m-189.67m120.60m15.00--0.6766--7.95-4.22-4.220.1241.140.0441--1.171,043,000.00-55.10-61.04-69.25-74.66-1,086.11---1,250.18-1,186.01----0.0023---39.63---5.96------
Alzinova AB0.00-10.48m125.75m----1.18-----0.4388-0.43880.003.400.00-------10.34-8.30-10.66-8.62-----------476.840.00-------16.19--28.46--
Toleranzia AB0.00-7.89m126.23m----1.07-----0.0673-0.06730.001.100.00-------6.19-12.63-6.43-13.30------------0.0069-------27.68--55.48--
Peptonic Medical AB35.04m-71.35m131.82m----0.7808--3.76-0.2277-0.22770.10750.14350.41881.043.39---85.26-38.78-113.84-45.5560.91---203.61-223.580.5254-38.840.2223---10.10---115.39---16.66--
2cureX AB7.76k-27.99m133.14m----2.71--17,162.84-1.76-1.760.00052.880.0001--0.0011---42.42-23.18-44.73-27.65-176,600.00-88,517.02-360,787.50-94,872.34----0.00-------158.70---37.81--
Coegin Pharma AB0.00-34.52m133.51m----5.64-----0.0516-0.05160.000.02640.00-------142.04---158.13-------------1,546.570.00------41.29------
Data as of Feb 03 2023. Currency figures normalised to Nordic Nanovector ASA's reporting currency: Norwegian Krone NOK

Institutional shareholders

13.94%Per cent of shares held by top holders
HolderShares% Held
Folketrygdfondetas of 31 Dec 20217.82m6.74%
Fj�rde AP-fondenas of 31 Dec 20214.00m3.45%
Handelsbanken Fonder ABas of 31 Jan 20232.16m1.86%
Nordea Investment Management AB (Norway)as of 30 Jun 2022895.05k0.77%
Storebrand Asset Management ASas of 31 Oct 2022605.65k0.52%
Dimensional Fund Advisors LPas of 31 Oct 2022376.39k0.32%
Max Mitteregger Kapitalf�rvaltning ABas of 31 Dec 2016300.00k0.26%
Dimensional Fund Advisors Ltd.as of 31 May 202220.69k0.02%
SSgA Funds Management, Inc.as of 05 Jan 20231.36k0.00%
ATL 12 Capital Gesti�n SGIIC SAas of 30 Sep 20220.000.00%
More ▼
Data from 31 Dec 2016 - 02 Feb 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.